U.S. Health Secretary Robert F. Kennedy Jr. reignited vaccine controversy this week by repeating debunked claims about the MMR (Measles, Mumps, Rubella) vaccine during a growing measles outbreak, one of the worst in 25 years. Kennedy alleged that the vaccine contains cells from aborted fetuses and questioned the efficacy of the mumps component, sparking backlash from medical experts.
The outbreak, centered in a Mennonite community in Texas, has spread to Oklahoma, Kansas, and New Mexico, infecting hundreds and killing two children. Scientists warn the U.S. may lose its measles elimination status, achieved in 2000, if vaccination rates continue to decline.
Kennedy, long known for promoting vaccine skepticism, claimed in a News Nation interview that religious groups avoid the MMR vaccine due to "aborted fetus debris." However, experts clarified that while the rubella component is produced using a fetal cell line from a 1960s abortion, no actual fetal cells are present in the final vaccine. These lab-grown cells have been replicated for decades and are filtered out during production, leaving only a purified, weakened virus.
According to Dr. Miriam Laufer from the University of Maryland and Dr. Paulo Verardi from the University of Connecticut, any DNA remnants in the final vaccine are negligible—measured in billionths of a gram.
Kennedy also said the mumps portion of the vaccine “doesn’t work” and lacked proper safety testing. However, the CDC reports that two doses of MMR provide about 86% protection against mumps. While immunity may wane over time, vaccinated individuals typically experience milder symptoms if infected.
The Department of Health and Human Services declined to comment on Kennedy’s statements, which many experts say undermine public trust in proven vaccine science.


Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Trump Signs Order to Ease Federal Marijuana Rules, Signaling Major Policy Shift
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Dan Bongino to Step Down as FBI Deputy Director After Brief, Controversial Tenure
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
U.S.-Russia Talks in Miami Raise Hopes for Potential Ukraine War Deal
Trump Announces $1,776 Cash Bonus for U.S. Military Personnel Ahead of Christmas
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Barham Salih Elected as Next UN High Commissioner for Refugees
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 



